Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial

Movement Disorders

Volumn 31, Issue 11, 2016, Pages 1649-1657

  Poewe, Werner ^a   Burbaud, Pierre ^b,c   Castelnovo, Giovanni ^d   Jost, Wolfgang H ^e   Ceballos Baumann, Andres O ^f   Banach, Marta ^g   Potulska Chromik, Anna ^h   Ferreira, Joaquim J ⁱ   Bihari, Katalin ^j   Ehler, Edvard ^k   Bares, Martin ^l,m,n   Dzyak, Lyudmyla A ^o,p   Belova, Anna N ^q   Pham, Emmanuel ^r   Liu, Wenzhong Jerry ^r,s   Picaut, Philippe ^q  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d DEPARTMENT OF NEUROLOGY   (France)

^e UNIVERSITY OF FREIBURG   (Germany)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^h MEDICAL UNIVERSITY OF WARSAW   (Poland)

ⁱ INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^j Epilepsy Center   (Hungary)

^k Department of Neurology   (Czech Republic)

^l MASARYK UNIVERSITY   (Czech Republic)

^m ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

ⁿ UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^o Dnipropetrovsk State Medical Academy   (Ukraine)

^p Department of Neurology ^*  (Ukraine)

^q PRIVOLZHSKY RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^r IPSEN   (France)

^s Sanbio   (United States)

more..

Author keywords

abobotulinumtoxinA solution for injection; cervical dystonia; Toronto Western Spasmodic Torticollis Rating Scale

Indexed keywords

BOTULINUM TOXIN A; NEUTRALIZING ANTIBODY; PLACEBO; ACETYLCHOLINE RELEASE INHIBITOR;

ADULT; ARTICLE; ASTHENIA; BACKACHE; CERVICAL DYSTONIA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DYSPHAGIA; DYSPHONIA; ELECTROMYOGRAM; ENDOMETRIUM POLYP; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOGENICITY; INFLUENZA; INJECTION SITE PAIN; INTERACTIVE VOICE RESPONSE SYSTEM; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT PLEURA EFFUSION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MUSCULOSKELETAL PAIN; NECK PAIN; OPEN STUDY; OROPHARYNX PAIN; OUTCOME ASSESSMENT; PAIN SEVERITY; PELVIC PAIN; PERICARDIAL EFFUSION; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINOPHARYNGITIS; SIDE EFFECT; STREPTOCOCCUS PNEUMONIA; TORONTO WESTERN SPASMODIC TORTICOLLIS RATING SCALE; TREATMENT DURATION; UPPER EXTREMITY DEEP VEIN THROMBOSIS; VISUAL ANALOG SCALE; CLINICAL TRIAL; COMPARATIVE STUDY; MIDDLE AGED; PROCEDURES; SEVERITY OF ILLNESS INDEX; TORTICOLLIS;

ACETYLCHOLINE RELEASE INHIBITORS; ADULT; BOTULINUM TOXINS, TYPE A; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TORTICOLLIS;

EID: 84992505012     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26760     Document Type: Article

References (21)

1. Jankovic J, Tsui J, Bergeron C. Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. Parkinsonism Relat Disord 2007;13:411–416.
2. Molho ES, Agarwal N, Regan K, Higgins DS, Factor SA. Effect of cervical dystonia on employment: a retrospective analysis of the ability of treatment to restore premorbid employment status. Mov Disord 2009;24:1384–1387.
3. Albanese A, Asmus F, Bhatia KP, et al. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol 2011;18:5–18.
4. Marsh WA, Monroe DM, Brin MF, Gallagher CJ. Systematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystonia. BMC Neurol 2014;14:91.
5. Swope D, Barbano R. Treatment recommendations and practical applications of botulinum toxin treatment of cervical dystonia. Neurol Clin 2008;26(suppl 1):54–65.
6. Costa J, Espirito-Santo C, Borges A, et al. Botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev 2005:CD004315.
7. Jost WH, Blumel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia. Drugs 2007;67:669–683.
8. Keam SJ, Muir VJ, Deeks ED. Botulinum toxin A (Dysport(R)): in dystonias and focal spasticity. Drugs 2011;71:1043–1058.
9. Panjwani N, O'Keeffe R, Pickett A. Biochemical, functional and potency characteristics of type A botulinum toxin in clinical use. Botulinum J 2008;1:153–166.
10. Truong D, Brodsky M, Lew M, et al. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord 2010;16:316–323.
11. Truong D, Duane DD, Jankovic J, et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord 2005;20:783–791.
12. Medical Dictionary for Regulatory Activities. 2014. http://www.meddra.org/. Accessed June 6, 2014.
13. Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 1988;7:889–894.
14. Hauser RA, Truong D, Hubble J, et al. AbobotulinumtoxinA (Dysport) dosing in cervical dystonia: an exploratory analysis of two large open-label extension studies. J Neural Transm 2013;120:299–307.
15. Mohammadi B, Buhr N, Bigalke H, Krampfl K, Dengler R, Kollewe K. A long-term follow-up of botulinum toxin A in cervical dystonia. Neurol Res 2009;31:463–466.
16. Pappert EJ, Germanson T, Myobloc/Neurobloc European Cervical Dystonia Study Group. Botulinum toxin type B vs. type A in toxin-naive patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord 2008;23:510–517.
17. Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999;53:1431–1438.
18. Charles D, Brashear A, Hauser RA, et al. Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia. Clin Neuropharmacol 2012;35:208–214.
19. Comella CL, Jankovic J, Shannon KM, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005;65:1423–1429.
20. Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S, Group USXCDS. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci 2011;308:103–109.
21. Dressler D, Paus S, Seitzinger A, Gebhardt B, Kupsch A. Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia. J Neurol Neurosurg Psychiatry 2013;84:1014–1019.